MDGL - CIK 0001157601
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported revenue of $958.40M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $958.40M | +432.1% |
| FY 2024 | $180.13M | - |
| FY 2023 | $0.00 | - |
| FY 2022 | $0.00 | - |
| FY 2021 | $0.00 | - |
| FY 2020 | $0.00 | - |
| FY 2019 | $0.00 | - |
| FY 2018 | $0.00 | - |
| FY 2017 | $0.00 |
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported revenue of $958.40M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2012 and fiscal 2025, MADRIGAL PHARMACEUTICALS, INC.'s revenue grew from $147.00K to $958.40M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -100.0% |
| FY 2012 | $147.00K | - |